[{"id":"b7ba04ad-2e05-4858-90e2-5ecabf721773","acronym":"KeyImPaCT","url":"https://clinicaltrials.gov/study/NCT03516981","created_at":"2021-01-18T17:18:40.896Z","updated_at":"2024-07-02T16:35:17.597Z","phase":"Phase 2","brief_title":"A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)","source_id_and_acronym":"NCT03516981 - KeyImPaCT","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab (MK-4280) • quavonlimab (MK-1308) • favezelimab/pembrolizumab (MK-4280A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/28/2025","study_completion_date":" 06/28/2025","last_update_posted":"2024-02-26"}]